Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8747614 | 1.00 | MAPT (0.44) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL8747512 | 0.83 | KMT2A (0.50) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL22351602 | 0.80 | ESRRG (0.41) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL9546435 | 0.78 | KMT2A (0.46) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL20569227 | 0.78 | KMT2A (0.58) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL20569230 | 0.78 | KMT2A (0.58) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL22351603 | 0.77 | ESRRG (0.40) | MAPTNPC1RAB9AKDM4ECA1 | |
| SCHEMBL18821759 | 0.76 | KMT2A (0.59) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL18243834 | 0.76 | KMT2A (0.67) | MAPTNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL18821811 | 0.76 | KMT2A (0.67) | MAPTNPC1RAB9AKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117970589-A | Optical imaging lens | 浙江舜宇光学有限公司 | 2024-05-03 | — | — | CN | claimed |
| EP-0642669-A1 | PEPTIDE SUB-LIBRARY KITS. | FURKA ARPAD (HU) | 1995-03-15 | — | — | EP | claimed |
| WO-1993024517-A2 | PEPTIDE SUB-LIBRARY KITS | FURKA ARPAD (HU) | 1993-12-09 | — | — | WO | claimed |
| US-20260063630-A1 | CAPTURE, PURIFICATION, AND RELEASE OF BIOLOGICAL SUBSTANCES USING A SURFACE COATING | ACADEMIA SINICA (TW) | 2026-03-05 | — | — | US | disclosed |
| US-12258401-B2 | Anti-CD47 combination therapy | TEVA PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2025-03-25 | — | — | US | disclosed |
| US-12241101-B2 | Microorganism producing polyunsaturated fatty acid and method for producing polyunsaturated fatty acid | KYOWA HAKKO BIO CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| CN-117970589-A | Optical imaging lens | 浙江舜宇光学有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117916270-A | Epithelial cell adhesion molecule (EPCAM) inhibitors and WNT inhibitor-binding cancer treatments | 周美吟 | 2024-04-19 | — | — | CN | disclosed |
| CN-117717604-A | anti-CD 47 combination therapy | 梯瓦制药澳大利亚股份有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117677397-A | Epithelial cell adhesion molecule (EPCAM) inhibitors and liver growth factor receptor (HGFR) inhibitors for the treatment of cancer | 周美吟 | 2024-03-08 | — | — | CN | disclosed |
| CN-117462668-A | Methods of treating tumors with anti-PD-1 antibodies | 百时美施贵宝公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-115530636-A | Heating cooker | 松下知识产权经营株式会社 | 2022-12-30 | — | — | CN | disclosed |
| US-20220259311-A1 | ANTI-CD47 COMBINATION THERAPY | TEVA PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2022-08-18 | — | — | US | disclosed |
| CN-114834114-A | Coating film for protecting optical member | 三菱化学株式会社 | 2022-08-02 | — | — | CN | disclosed |
| US-20220233712-A1 | EXOSOME COMPRISING STABILIZED RNA THERAPEUTICS | EVOX THERAPEUTICS LTD (GB) | 2022-07-28 | — | — | US | disclosed |
| EP-3965828-A1 | EXOSOME COMPRISING STABILIZED RNA THERAPEUTICS | Evox Therapeutics Limited (GB) | 2022-03-16 | — | — | EP | disclosed |
| US-20220048962-A1 | SYSTEMS AND METHODS FOR MODULATING RNA | THE UNIVERSITY OF CHICAGO (US) | 2022-02-17 | — | — | US | disclosed |
| EP-0642669-B1 | PEPTIDE SUB-LIBRARY KITS | FURKA ARPAD (HU) | 1997-03-12 | — | — | EP | disclosed |
| EP-0642669-A1 | PEPTIDE SUB-LIBRARY KITS. | FURKA ARPAD (HU) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993024517-A2 | PEPTIDE SUB-LIBRARY KITS | FURKA ARPAD (HU) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260063630-A1 | CAPTURE, PURIFICATION, AND RELEASE OF BIOLOGICAL SUBSTANCES USING A SURFACE COATING | EPCAM, SELL, CD47 | MAPT 1404/4885NPC1 494/4885RAB9A 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.